US Bancorp DE Acquires 4,324 Shares of Biogen Inc. $BIIB

US Bancorp DE raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 25.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 21,433 shares of the biotechnology company’s stock after acquiring an additional 4,324 shares during the period. US Bancorp DE’s holdings in Biogen were worth $3,002,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Empowered Funds LLC boosted its holdings in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in Biogen during the second quarter valued at $216,000. Envestnet Asset Management Inc. lifted its holdings in Biogen by 7.2% in the second quarter. Envestnet Asset Management Inc. now owns 56,076 shares of the biotechnology company’s stock valued at $7,043,000 after acquiring an additional 3,782 shares during the period. Finally, Y Intercept Hong Kong Ltd boosted its position in Biogen by 243.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 6,318 shares of the biotechnology company’s stock worth $793,000 after purchasing an additional 4,480 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Insider Activity at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BIIB shares. Tudor Pickering set a $201.00 price objective on shares of Biogen in a report on Monday, February 9th. Morgan Stanley set a $190.00 price objective on shares of Biogen in a research report on Sunday, February 8th. Wedbush lifted their target price on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Mizuho upped their price target on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Twelve analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $205.04.

Biogen Stock Down 2.1%

Shares of BIIB opened at $184.02 on Wednesday. The business’s 50 day moving average is $182.43 and its 200 day moving average is $164.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $202.41. The company has a market capitalization of $27.01 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the firm posted $3.44 EPS. The company’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.